Published in J Clin Oncol on August 20, 2007
Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int (2008) 1.08
Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology (2010) 1.06
Prediction models in urology: are they any good, and how would we know anyway? Eur Urol (2009) 0.96
The value of personalised risk information: a qualitative study of the perceptions of patients with prostate cancer. BMJ Open (2013) 0.92
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys (2010) 0.90
Family physicians could help in predicting life expectancy without prostate cancer. J Clin Oncol (2008) 0.79
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA (2008) 3.55
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol (2011) 3.48
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Chemotherapy for teratoma with malignant transformation. J Clin Oncol (2003) 2.06
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res (2003) 1.99
Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res (2005) 1.98
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) (2010) 1.92
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol (2009) 1.91
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev (2005) 1.80
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2011) 1.77
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer (2008) 1.65
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol (2008) 1.62
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res (2005) 1.61
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate (2012) 1.54
Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol (2003) 1.51
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol (2011) 1.51
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology (2013) 1.44
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol (2008) 1.43
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int (2011) 1.41
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol (2011) 1.39
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Development of an integrated prostate cancer research information system. Clin Genitourin Cancer (2006) 1.36
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A (2012) 1.34
Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev (2005) 1.33
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol (2010) 1.32
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer (2004) 1.31
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A (2013) 1.30
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res (2009) 1.27
Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.26
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 1.25
Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Chemotherapy for prostate cancer. Urology (2002) 1.18
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila) (2011) 1.17
Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia (2007) 1.14
Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer (2004) 1.14
Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.13
Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol (2011) 1.12
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10
Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology (2006) 1.10
Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res (2010) 1.10
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int (2012) 1.09
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer (2012) 1.07
Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate (2008) 1.06
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int (2008) 1.06